IL147952A0 - G protein-coupled receptor up-regulated in prostate cancer and uses thereof - Google Patents

G protein-coupled receptor up-regulated in prostate cancer and uses thereof

Info

Publication number
IL147952A0
IL147952A0 IL14795200A IL14795200A IL147952A0 IL 147952 A0 IL147952 A0 IL 147952A0 IL 14795200 A IL14795200 A IL 14795200A IL 14795200 A IL14795200 A IL 14795200A IL 147952 A0 IL147952 A0 IL 147952A0
Authority
IL
Israel
Prior art keywords
prostate cancer
protein
phor
coupled receptor
regulated
Prior art date
Application number
IL14795200A
Other languages
English (en)
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of IL147952A0 publication Critical patent/IL147952A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL14795200A 1999-10-05 2000-10-05 G protein-coupled receptor up-regulated in prostate cancer and uses thereof IL147952A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15790299P 1999-10-05 1999-10-05
PCT/US2000/027543 WO2001025434A1 (fr) 1999-10-05 2000-10-05 Recepteur couple a une proteine g regule positivement dans le cancer de la prostate et utilisation

Publications (1)

Publication Number Publication Date
IL147952A0 true IL147952A0 (en) 2002-08-14

Family

ID=22565799

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14795200A IL147952A0 (en) 1999-10-05 2000-10-05 G protein-coupled receptor up-regulated in prostate cancer and uses thereof

Country Status (13)

Country Link
EP (2) EP2003202B1 (fr)
JP (2) JP4272376B2 (fr)
AT (2) ATE524549T1 (fr)
AU (2) AU779685B2 (fr)
CA (1) CA2385032C (fr)
CY (2) CY1110059T1 (fr)
DE (1) DE60041073D1 (fr)
DK (2) DK1220913T3 (fr)
ES (2) ES2371212T3 (fr)
HK (1) HK1048494B (fr)
IL (1) IL147952A0 (fr)
PT (2) PT1220913E (fr)
WO (1) WO2001025434A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
CA2447564A1 (fr) * 2001-05-15 2002-11-21 Agensys, Inc. Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers
EP1864131B1 (fr) * 2005-03-03 2011-09-28 ChemCom S.A. Ligand naturel du récepteur couplé aux proteines g (gpcr) rcc356 et utilisations de ce ligand
JPWO2007119515A1 (ja) * 2006-03-28 2009-08-27 昇志 佐藤 新規腫瘍抗原ペプチド
JP2012196211A (ja) * 2012-04-10 2012-10-18 Japan Science & Technology Agency 前立腺癌マーカポリペプチド、該ポリペプチドに対する抗体、及び該ポリペプチドを利用した前立腺癌の診断方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US4975287A (en) 1989-09-01 1990-12-04 Wm. Wrigley Jr. Company Gum composition containing protein macrocolloids
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
WO1992000311A1 (fr) 1990-06-27 1992-01-09 Princeton University Sondes de detection de p53 mutant
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
EP0773952B1 (fr) 1994-07-20 2003-11-12 The General Hospital Corporation Systemes de detection d'interactions entre proteines
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
NZ502795A (en) 1995-04-11 2001-09-28 Gen Hospital Corp Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
EP0832122A4 (fr) 1995-06-05 1999-08-25 Human Genome Sciences Inc Recepteur hpraj70 de proteine g humaine
WO1997041255A1 (fr) 1996-04-26 1997-11-06 Massachusetts Institute Of Technology Methode de criblage a l'aide de trois hybrides
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
EP0953039B1 (fr) 1996-10-15 2007-08-29 The Regents Of The University Of California Modeles animaux de la progression du cancer de la prostate chez l'humain
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CA2296287A1 (fr) * 1997-08-01 1999-02-11 Genset Marqueurs sequences 5' exprimes pour proteines secretees exprimees dans la prostate
JP2002520054A (ja) * 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
CA2345045A1 (fr) * 1998-10-06 2000-04-13 Incyte Pharmaceuticals, Inc. Proteines de recepteurs couples a des proteines g
WO2000020590A2 (fr) * 1998-10-06 2000-04-13 Incyte Pharmaceuticals, Inc. Proteines de recepteurs couples a des proteines g

Also Published As

Publication number Publication date
CY1110059T1 (el) 2015-01-14
JP4875671B2 (ja) 2012-02-15
ATE524549T1 (de) 2011-09-15
CA2385032A1 (fr) 2001-04-12
PT1220913E (pt) 2009-02-16
AU2005201916A1 (en) 2005-06-02
AU779685B2 (en) 2005-02-03
AU2005201916B2 (en) 2008-06-19
PT2003202E (pt) 2012-01-02
JP4272376B2 (ja) 2009-06-03
AU7755300A (en) 2001-05-10
DK2003202T3 (da) 2012-01-16
CY1112202T1 (el) 2015-12-09
EP2003202A2 (fr) 2008-12-17
DK1220913T3 (da) 2009-03-16
ATE417104T1 (de) 2008-12-15
WO2001025434A1 (fr) 2001-04-12
EP2003202A3 (fr) 2009-10-21
CA2385032C (fr) 2013-12-10
DE60041073D1 (de) 2009-01-22
EP1220913B1 (fr) 2008-12-10
ES2371212T3 (es) 2011-12-28
JP2003511029A (ja) 2003-03-25
JP2009050256A (ja) 2009-03-12
EP2003202B1 (fr) 2011-09-14
ES2316387T3 (es) 2009-04-16
AU2005201916A2 (en) 2005-08-25
HK1048494B (en) 2009-06-12
EP1220913A1 (fr) 2002-07-10
HK1048494A1 (en) 2003-04-04

Similar Documents

Publication Publication Date Title
MXPA02011142A (es) Plataforma de nanodispositivo multifuncional.
ATE478952T1 (de) 36p6d5: ausgeschiedenes tumorprotein
WO1998010069A3 (fr) Proteine e25a, ses procedes de production et d'utilisation
WO1999064576A3 (fr) Nouveaux genes humains et produits d'expression genique
EP1488007A4 (fr) Profilage d'expression genique dans des tissus tumoraux ponctionnes
EP0959896A4 (fr) Compositions a base de recepteur de la thyrotropine humaine
CY1112202T1 (el) Υποδοχεας συζευγμενος προς g πρωτεϊνη θετικως ρυθμισμενος σε καρκινο προστατη και χρησεις αυτου
WO2000012702A3 (fr) Genes humains exprimes de maniere differenciee dans un cancer colorectal
IL142194A0 (en) Gene expressed in prostate cancer
Trieb et al. Effects of hyperthermia on heat shock protein expression, alkaline phosphatase activity and proliferation in human osteosarcoma cells
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
WO2006037485A3 (fr) Procedes et kits pour la prevision d'un succes therapeutique et d'une survie exempte de rechute en therapie du cancer
Wu et al. Hormonal therapy for stomach cancer
IL143988A0 (en) Compositions and methods for intraductal gene therapy
McGinnis et al. Consequences of mutations in androgen receptor genes: molecular biology and behavior
WO2001090157A8 (fr) 98p7c3: proteine a homeodomaine fortement exprimee dans divers cancers
US6171818B1 (en) Protein having an anti-tumoral effect
Hogen et al. EP008/# 378 Comparative genomic analysis of ovarian clear cell carcinoma patients with and without a second primary malignancy
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
Lee et al. GHR106, the First in Class Antibody-based GnRH Antagonist for Broad Clinical Applications
WO2002077234A3 (fr) Compositions et methodes se rapportant aux genes et aux proteines specifiques du colon
AU2003247704A1 (en) Methods and compositions for diagnosing hepatocellular carcinoma
WO2004058167A3 (fr) Proteine specifique du sein exprimee dans le cancer, et ses methodes d'utilisation
MX2025004764A (es) Identificación y/o tratamiento de cáncer
WO2005108993A3 (fr) Diagnostic et therapeutique de maladies associees a la proteine kinase kinase kinase 6 activee par des mitogenes (map3k6)

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees